Disease modification in migraine: A concept that has come of age?

Headache

Volumn 43, Issue 2, 2003, Pages 135-143

  Loder, Elizabeth ^a   Biondi, David ^a  

^a and Red Sox Foundation and Massachusetts General Hospital Home Base Program   (United States)

Author keywords

Disability prevention; Disease modification; Disease progression; Migraine

Indexed keywords

ANALGESIC AGENT; ANTIINFLAMMATORY AGENT; ANTIMIGRAINE AGENT; BARBITURIC ACID DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAFFEINE; OPIATE; SUMATRIPTAN; TRIPTAN DERIVATIVE; UNCLASSIFIED DRUG;

BEHAVIOR MODIFICATION; CLINICAL RESEARCH; COGNITIVE THERAPY; COMBINATION CHEMOTHERAPY; DISABILITY; DISEASE COURSE; DISEASE SEVERITY; DRUG DEPENDENCE; DRUG DESIGN; DRUG EFFICACY; HEADACHE; HUMAN; LONG TERM CARE; MIGRAINE; PALLIATIVE THERAPY; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; RISK FACTOR;

HUMANS; MIGRAINE DISORDERS; RISK FACTORS; TIME FACTORS;

EID: 0037314040     PISSN: 00178748     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1526-4610.2003.03033.x     Document Type: Review

References (50)

1. Kremer JM. Rational use of new and existing disease-modifying agents in rheumatoid arthritis. Ann Intern Med. 2001;134:695-706.
2. Emery P. Disease modification in rheumatoid arthritis with leflunomide. Scand J Rheumatol. 1999;112:9-14.
3. Hernandez-Garcia C, Vargas E, Abasolo L, et al. Lag time between onset of symptoms and access to rheumatology care and DMARD therapy in a cohort of patients with rheumatoid arthritis. J Rheumatol. 2000;27:2323-2328.
4. Chan PL, Holford NH. Drug treatment effects on disease progression. Annu Rev Pharmacol Toxicol. 2001;41:625-659.
5. Hillard TC, Whitecroft SJ, Marsh MS, et al. Long-term effects of transdermal and oral hormone replacement therapy on post-menopausal bone loss. Osteoporosis Int. 1994;4:341-348.
6. Mora-Macia J, Cases A, Calero F, Barcelo P. Effect of angiotensin II receptor blockade on renal disease progression in patients with non-diabetic chronic renal failure. Nephrol Dial Transplant. 2001;16(suppl 1):82-84.
7. Granella F, Cavallini A, Sandrini G, Manzoni GC, Nappi G. Long-term outcome of migraine. Cephalalgia. 1998;18(suppl 2):30-33.
8. Scher AI, Stewart WF, Liberman J, Lipton RB. Prevalence of frequent headache in a population sample. Headache. 1998;38:497-506.
9. Silberstein SD, Lipton RB, Sliwinski M. Classification of daily and near-daily headaches: field trial of revised IHS criteria. Neurology. 1996;47:871-875.
10. Scher AI, Lipton RB, Stewart WF. Natural history and prognostic factors for chronic daily headache: results from the Frequent Headache Epidemiology Study [abstract]. Neurology. 2002;58(suppl 3):A171.
11. Lu SR, Fuh JL, Chen WT, Juang KD, Wang SJ. Chronic daily headache in Taipei, Taiwan: prevalence, follow-up and outcome predictors. Cephalalgia. 2001;20:900-906.
12. Lipton RB, Stewart WF, Simon D. Work-related disability: results from the American Migraine Study. Cephalalgia. 1996;16:231-238.
13. Jacobson GP, Ramadan NM, Norris L, Newman CW. The Henry Ford Hospital Headache Disability Inventory (HDI). Neurology. 1994;4:837-842.
14. Lipton RB, Stewart WF, Stone AM, et al. Stratified care vs. step care strategies for migraine. The Disability in Strategies of Care (DISC) study. JAMA. 2000;284:2599-2605.
15. Welch KM, Nagesh V, Aurora SK, Gelman N. Peri-aqueductal gray matter dysfunction in migraine: cause or the burden of illness? Headache. 2001;41: 629-637.
16. Chronicle E, Mulleners W. Might migraine damage the brain? Cephalalgia. 1994;14:415-418.
17. Khalil NM, Legg NJ, Anderson DJ. Long term decline of P100 amplitude in migraine with aura. J Neurol Neurosurg Psychiatry. 2000;69:507-511.
18. Wong TY, Klein R, Sharrett AR, et al. Cerebral white matter lesions, retinopathy, and incident clinical stroke. JAMA. 2002;288:67-74.
19. Mulder EJ, Linssen WH, Passchier J, Orlebeke JF, de Geus EJ. Interictal and postictal cognitive changes in migraine. Cephalalgia. 1999;19:557-565.
20. Sandor PS, Mascia A, Seidel L, de Pasqua V, Schoenen J. Subclinical cerebellar impairment in the common types of migraine: a three-dimensional analysis of reaching movements. Ann Neurol. 2001;49:668-672.
21. Jacome DE. Neuromuscular transmission in migraine: a single-fiber EMG study in clinical sub-groups. Neurology. 2002;58:1316-1367.
22. Kraus JE. Sensitization phenomena in psychiatric illness: lessons from the kindling model. J Neuropsychiatry Clin Neurosci. 2000;12:328-343.
23. Bendtsen L. Central sensitization in tension-type headache - possible pathophysiological mechanisms. Cephalalgia. 2000;20:486-508.
24. Strassman AM, Raymond SA, Burstein R. Sensitization of meningeal sensory neurons and the origin of headaches. Nature. 1996;384:560-564.
25. Turner JA, Franklin G, Turk DC. Predictors of chronic disability in injured workers: a systematic literature synthesis. Am J Ind Med. 2000;38:707-722.
26. Weiser S, Cedraschi C. Psychosocial issues in the prevention of chronic low back pain - a literature review. Baillieres Clin Rheum. 1992;6:657-684.
27. New Zealand evidence-based guidelines: Guide to assessment of psychosocial yellow flags in acute low back pain: risk factors for long term disability and work loss. Accessed at: www.nzgg.org.nz/library/gl-complete/backpain2/full; January 22, 2002.
28. Linton SJ. Prevention of disability due to chronic muskuloskeletal pain. In: Wall PD, Melzack R, eds. Textbook of Pain. Edinburgh: Churchill Livingstone; 1999:1536-1546.
29. Schulman EA, Cady RK, Henry D, et al. Effectiveness of sumatriptan in reducing productivity loss due to migraine: results of a randomized, double-blind, placebo-controlled clinical trial. Mayo Clin Proc. 2000;75:782-789.
30. Santanello NC, Polis AB, Hartmaier SL, Kramer MS, Block GA, Silberstein SD. Improvement in migraine-specific quality of life in a clinical trial of rizatriptan. Cephalalgia. 1997;17:867-872.
31. Farmer K, Cady R, Bleiberg J, et al. Sumatriptan nasal spray and cognitive function during migraine: results of an open label study. Headache. 2002;41:377-384.
32. Katsarava Z, Fritsche G, Muessig M, Diener HC, Limmroth V. Clinical features of withdrawal headache following overuse of triptans and other headache drugs. Neurology. 2001;57:1694-1698.
33. Packer M, Cohn JN. Consensus recommendations for the management of chronic heart failure. Am J Cardiol. 1999;83:1A-38A.
34. Silberstein SD for the US Headache Consortium. Evidence-based guidelines for migraine headache in the primary care setting: pharmacological management of acute attacks. Neurology. 2000;55:754-763.
35. Mathew NT, Kurman R, Perez F. Drug-induced refractory headache - clinical features and management. Headache. 1990;30:634-638.
36. nd Annual Scientific Meeting of the American Headache Society; June 2000; Montreal, Quebec.
37. Wober C, Wober-Bingol C, Koch G, Wessely P. Long-term results of migraine prophylaxis with flunarizine and beta-blockers. Cephalalgia. 1991;11: 251-256.
38. Scharff L, Marcus DA, Turk DC. Maintenance of effects in the nonmedical treatment of headaches during pregnancy. Headache. 1996;36:285-290.
39. Rothrock JF, Kelly NM, Brody ML, Golbeck A. A differential response to treatment with divalproex sodium in patients with intractable headache. Cephalalgia. 1994;14:241-244.
40. Gray RN, Schnider P, Aull S, et al. Drug Treatments for the Prevention of Migraine Headache. Technical Review 2.3. (Prepared for the Agency for Health Care Policy and Research under Contract No. 290-94-2025.) Available from: the National Technical Information Service (Accession No. 127953); 1999.
41. Ploghaus A, Tracey I, Gati JS, et al. Dissociating pain from its anticipation in the human brain. Science. 1999;284:1979-1981.
42. Goslin RE, Gray RN, McCrory DC, Penzien DB, Rains JC, Hasselblad V. Behavioral and Physical Treatments for Migraine Headache. Technical Review 2.2. (Prepared for the Agency for Health Care Policy and Research.) Available from: the National Technical Information Service (Accession No. 127946);1999.
43. th Annual Scientific Meeting of the American Headache Society; June 2002; Seattle, Washington.
44. Hernandez-Latorre MA, Roig M. Natural history of migraine in childhood. Cephalalgia. 2000;20: 573-579.
45. Grazzi L, Andrasik F, D'Amico D, et al. Behavioral and pharmacologic treatment of transformed migraine with analgesic overuse: outcome at 3 years. Headache. 2002;42:483-490.
46. Cologno D, Torelli P, Manzoni GC. Possible predictive factors in the prognosis of migraine with aura. Cephalalgia. 1999;19:824-830.
47. Balottin U, Borgatti R, Zambrino C, Lanzi G. Clinical characteristics and long-term outcome of migraine with aura in children and adolescents. Dev Med Child Neurol. 1997;39:26-30.
48. Diener HC, Dichgans J, Scholz E, Geiselhart S, Gerber WD, Bille A. Analgesic-induced chronic headache: long-term results of withdrawal therapy. J Neurol. 1989;236:9-14.
49. Suhr B, Evers S, Bauer B, Gralow I, Grotemeyer KH, Husstedt IW. Drug-induced headache: long-term results of stationary versus ambulatory withdrawal therapy. Cephalalgia. 1999;19:44-49.
50. Schnider P, Aull S, Baumgartner C, et al. Long-term outcome of patients with headache and drug abuse after inpatient withdrawal: five-year follow-up. Cephalalgia. 1996;33:55-62.